Anti-cancer therapy and clinical trial considerations for gynecologic oncology patients during the COVID-19 pandemic crisisShort communication Published on 2020-07-012022-10-05 Journal: Gynecologic oncology [Category] 임상, [키워드] addition alteration Cancer Care Chemotherapy clinical trial clinical trials co-morbidities Consensus Contact COVID 19 COVID-19 COVID-19 pandemic develop deviation effort Factor Health high risk immunosuppressive impacted initial IRB less limit morbidity Mortality objective occur Older oncology patient pandemic Patient patient safety recommendation regimen Regulatory resource resources Result risk Society Sponsor therapy Treatment Trial [DOI] 10.1016/j.ygyno.2020.04.694 [Article Type] Short communication
How is immunosuppressive status affecting children and adults in SARS-CoV-2 infection? A systematic reviewArticle Published on 2020-07-012023-06-19 Journal: The Journal of Infection [Category] Fulltext, SARS, [키워드] Adults Cancer children Immunosuppression SARS-CoV-2 Transplant [DOI] 10.1016/j.jinf.2020.04.026 PMC 바로가기
Considerations for interactions of drugs used for the treatment of COVID-19 with anti-cancer treatmentsReview article Published on 2020-07-012022-10-05 Journal: Critical Reviews in Oncology/Hematology [Category] SARS, 치료법, [키워드] anti-cancer treatment anticancer Cancer caused Chemotherapy chemotherapy drugs COVID-19 drug drug interaction General population hepatic impairment increased risk Infection Interaction Patient renal reported risk SARS-CoV2 SARS-CoV2 infection Treatment treatments for COVID-19 [DOI] 10.1016/j.critrevonc.2020.102982 [Article Type] Review article
Guide for Nuclear Medicine Applications During the COVID-19 OutbreakReview Published on 2020-06-292022-10-31 Journal: Molecular Imaging and Radionuclide Therapy [Category] COVID-19, [키워드] application Asymptomatic Cancer clinical status clinics Computerized tomography coronavirus country COVID-19 COVID-19 outbreak COVID-19 test CT finding defined described diagnosis of COVID-19 diagnostic Disinfection disseminate early diagnosis evaluated guide hygiene Infection infection protection rules infection risk International lung measure Medicine Ministry of Health nuclear nuclear medicine staff pandemic Patient Personal protective equipment positron emission tomography/computerized tomography Prevent pulmonary involvement questionnaire Spread spread of COVID-19 Symptom therapeutic Treatment Turkey Viral pneumonia virus WHO Wuhan, China [DOI] 10.4274/mirt.galenos.2020.33600 PMC 바로가기 [Article Type] Review
Treating Hematologic Malignancies During a Pandemic: Utilizing Telehealth and Digital Technology to Optimize CareOncology Published on 2020-06-262022-10-31 Journal: Frontiers in Oncology [Category] COVID-19, [키워드] Cancer Care care at home Chemotherapy Complication COVID-19 Digital digital technology disease global pandemic healthcare innovation healthcare worker help highest mitigate outbreak pandemic Patient Patient centered care patients remains uncertain reported respiratory risk SARS CoV-2 technology telehealth the patient treating Treatment Wuhan, China [DOI] 10.3389/fonc.2020.01183 PMC 바로가기 [Article Type] Oncology
COVID-19 and cancer researchEditorial Published on 2020-06-262022-10-04 Journal: British Journal of Cancer [Category] SARS, 진단, [키워드] approach Cancer cancer patient COVID-19 COVID-19 pandemic Effect Impact management outcomes Research response [DOI] 10.1038/s41416-020-0960-1 PMC 바로가기 [Article Type] Editorial
Dual Challenge of Cancer and COVID-19: Impact on Health Care and Socioeconomic Systems in Asia PacificSpecial Articles Published on 2020-06-262022-10-31 Journal: JCO Global Oncology [Category] COVID-19, SARS, [키워드] acute respiratory syndrome Asia Cancer Care caused challenge chronic disease coronavirus country COVID-19 COVID-19 pandemic health care systems health system Impact Italy majority Spain Spread spread of COVID-19 System The United States [DOI] 10.1200/GO.20.00227 PMC 바로가기 [Article Type] Special Articles
Effect of hydroxychloroquine on COVID-19 prevention in cancer patients undergoing treatment: a structured summary of a study protocol for a randomised controlled trialLetter Published on 2020-06-262022-10-29 Journal: Trials [Category] COVID-19, SARS, [키워드] 1:1 Acute Lymphoid Leukemia acute myeloid leukemia age anticipated approval approved assigned blinded blocks Breast cancer calculated Cancer cancer patient cardiac disease chemotherapeutic agent chronic pulmonary disease clinical Colon cancer company Computed tomography control group cough COVID-19 COVID-19 symptom curative intent data analyst disease dissemination Effect element examined exclusion criteria Fever FIVE follow-up period High-resolution Hydroxychloroquine IgG antibody incidence of COVID-19 include Intervention investigated Iran leukemia Lungs lymphoid lymphoma Mashhad Medical Sciences novel nucleic acid amplification number objective occur outcome parallel-group participant Patient patients performed pharmaceutical Placebo primary end point produced Prophylaxis protocol randomised randomised controlled trial randomization sequence Randomly randomly permuted blocks recruitment Registered registration date registry respiratory tract infection Sample size sensitivity Shortness of breath specific IgM status Study protocol Symptom Tablet the patient the SARS-CoV-2 virus total sample size treated Treatment Trial triple-blind two group Two-arm university website [DOI] 10.1186/s13063-020-04485-x PMC 바로가기 [Article Type] Letter
Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocolLetter Published on 2020-06-262022-10-29 Journal: Trials [Category] Coronavirus, SARS, [키워드] 1:1 24 hour Administered airway allocation concealment Alpha ambient analysed aneurysms Anticoagulant treatment anticoagulation antiplatelet Arm arterial assigned Atrial fibrillation bleeding bleeding event block size Blood BMI Body Breastfeeding breath calculated Cancer clinical clinically Coagulopathy Concomitant conjunctival Continuous contributed Control control group Controlled trial corpus COVID-19 COVID19 criteria Critical D-dimer D-dimer level Day death defined detect diagnostic discharged disease severity dissemination dosage dose effective Efficacy and safety element enoxaparin Epistaxis EudraCT event events expected fibrinogen level gingival bleeding group Haemoglobin haemoptysis health-care hematemesis hematoma hemodynamic heparin High dose high risk history hospital discharge Hospital stay hospitalized patient hypersensitivity Hypothesis IL-6 Impaired impairing improvement IMV In-hospital indication initiated Inpatient INR internal Intervention intervention group Intra-articular intramuscular invasive Invasive mechanical ventilation involved Italian Italy laboratory parameter LMWH low dose low-molecular weight heparin macroscopic Major major bleeding management Mechanical mechanical ventilation medical intervention Medicine Modena NIV Non-invasive number objective occur Occurrence open label ophthalmic oral anticoagulant outcome oxygen paO2/fiO2 parallel group participant pathology Patient performed Pharyngeal swab plasma Platelet Pneumonia positive pregnancy test Presence pressure Primary outcome prophylactic dose prosthetic protocol random randomisation randomised randomised controlled randomised controlled trial randomization Rate receiving recorded recruited Rectal Bleeding reduce reduction in Registered renal function reported required respiratory risk risk of death Sample size SARS-CoV-2 secondary secure Severe COVID-19 pneumonia severe disease significantly Spontaneous standard oxygen therapy Stata status stratified stroke study drug Study protocol subcutaneously surgical susceptible symptomatic syndrome therapeutic dose therapy thrombocytopenia time transfusion Treatment unfractionated heparin unit Vascular venipuncture Venous Thromboembolism web-based system website weight Withdrawal worsening [DOI] 10.1186/s13063-020-04475-z PMC 바로가기 [Article Type] Letter
Cancer management challenge in a developing country in COVID-19 pandemic: reflection of a group of Moroccan oncologistsSpecial Report Published on 2020-06-252022-10-31 Journal: Future Oncology [Category] COVID-19, SARS, [키워드] Cancer cancer patient country COVID-19 COVID-19 pandemic guidelines Health hospitalized patients Immunocompromised intensive care management Morocco oncologist oncology Palliative care Patient Prognosis PROTECT provided recommendations risk risk of COVID-19 SARS-CoV-2 Surveillance Treatment [DOI] 10.2217/fon-2020-0450 PMC 바로가기 [Article Type] Special Report